DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Disease-Modifying Antirheumatic Drug (DMARD) Market Size and Share Analysis – Growth Trends and Forecast (2026–2033)

The global Disease-Modifying Antirheumatic Drug (DMARD) Market is anticipated to grow at a CAGR of 3.5% during 2026–2033, with the market estimated at USD 23.72 Bn in 2026 and expected to reach approximately USD 30.18 Bn by 2033. The market growth is primarily driven by the rising prevalence of rheumatoid arthritis and other autoimmune disorders, increasing adoption of biologic and targeted synthetic DMARDs. According to a 2025 nationwide cohort study published in the journal Rheumatology, tumor necrosis factor inhibitors (TNFi) continued to be the most common first biologic therapy for rheumatoid arthritis patients, accounting for 62.6% of initial biologic or targeted synthetic DMARD prescriptions, this finding highlights the ongoing clinical reliance on advanced DMARD therapies in routine practice.

Key Takeaways

• Synthetic DMARDs (sDMARDs) segment is expected to lead the market with 54.8% in 2026. The segment’s rise is attributed to its sustained status as the chosen first-line treatment, affordability, wide availability, and strong support from treatment recommendations. A 2025 Pharmacoepidemiology study from the United States of 407,728 DMARD beginning occurrences among 229,365 rheumatoid arthritis patients.
• The Oral sector is expected to lead with 58.5% in 2026.  The segment’s rise is related to the widespread use of oral methotrexate and other csDMARDs, patient convenience, and rising usage of oral targeted synthetic medicines. A 2024 study published in the Journal of the Association of Physicians of India (JAPI) found that the majority of DMARD treatment strategies were oral therapies, with methotrexate being the most common DMARD prescribed (86% of rheumatoid arthritis patients), followed by hydroxychloroquine (52%) and sulfasalazine (42%).  
• Rheumatoid Arthritis segment is predicted to grow at a fastest pace of 67.4% in 2026. The segment is growing due to the increasing illness load and long-term need for disease-modifying therapies. Rheumatoid arthritis, psoriatic arthritis and spondyloarthritis represented more than 90% of all DMARD prescriptions supplied through homecare services, with rheumatoid arthritis being the predominant indication class, according to the 2025 Scottish national real-world prescribing study.
• The hospital pharmacy segment is predicted to capture the highest market share of 52.6% by 2026. The increase of the above-mentioned category is fueled by the need for specialist prescribing, biologic administration, monitoring and reimbursement policies. According to findings from the 2025 STRATEGE2 study, 97.7% of rheumatoid arthritis patients receiving biologic or targeted synthetic DMARDs remained on methotrexate therapy, while 83.2% continued methotrexate use after 12 months.
• North America is forecasted to account for the maximum market share of 41.3% in 2026 due to factors such as favorable reimbursement policies, rise in biologics usage, well-established healthcare facilities, and availability of rheumatologists. Biologic therapies have become widely used in North America. In 2025 study published in Arthritis Care & Research, the authors estimated that approximately 90% of rheumatoid arthritis patients in the United States are prescribed a tumor necrosis factor inhibitor (TNFi) as their first-line advanced therapy after having failed to respond adequately to conventional DMARDs.

Segmental Insights

Why are Synthetic DMARDs (sDMARDs) Emerging as the Leading Drug Type Segment?

Based on drug type, the Synthetic DMARDs (sDMARDs) segment is expected to dominate the Disease-Modifying Antirheumatic Drug (DMARD) Market in 2026 with a share of 54.8%. The segment’s growth is fueled by its sustained status as the preferred first-line treatment option, lower acquisition prices, widespread availability across healthcare systems, and strong backing from international treatment standards. Conventional DMARDs like methotrexate are still considered the main form of treatment for rheumatoid arthritis before moving on to other advanced forms of drugs.

According to a 2025 study published in Clinical Characteristics, Medication Use, and Short-Term Outcomes in Rheumatoid Arthritis Patients in the year 2025, it was stated that out of the total RA patients, 98.35% were being administered conventional synthetic DMARDs (csDMARDs).

In October 2025, Beta Drugs Limited announced that it had received approval from the Drug Controller General of India (DCGI) to launch India's first Methotrexate Oral Solution, a patient-friendly formulation indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, psoriasis, and other conditions.

Why is the Oral Route of Administration Acquiring the Largest Share?

The oral segment is projected to dominate with a 58.5% share by 2026. The increase is attributable to the widespread use of oral methotrexate, hydroxychloroquine and leflunomide and rising clinician trust in oral targeted synthetic DMARDs. Oral medicines are convenient, decrease the burden of administration and promote patient acceptance for long-term treatment.

Moreover, according to a patient outcomes survey conducted in 2024, roughly 68% of RA patients with rheumatoid arthritis preferred oral medications over injectables based on ease of use and minimal disruption during therapy sessions.

In April 2025, AbbVie announced that the European Commission approved RINVOQ® (upadacitinib), an oral Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA).

Why is Rheumatoid Arthritis Maintaining Its Dominance Among Indications?

By indication, the Rheumatoid Arthritis segment is projected to capture the largest share of 67.4% of the DMARD Market by 2026. The growth in this market segment can be attributed to the high prevalence of the disease, its chronicity, the need for lifelong disease modification, and treat-to-target approaches.

According to a 2025 Global Burden of Disease analysis published in Biomarker Research predicts the worldwide number of people with rheumatoid arthritis will grow by about 80% by 2050 versus current numbers, emphasizing the growing patient population needing DMARD therapy.

In December 2025, Adaptive Biotechnologies announced that it had entered into two non-exclusive agreements with Pfizer Inc. to advance research and drug discovery for rheumatoid arthritis.

Why are Hospital Pharmacies Leading the Distribution Channel Segment?

Based on distribution channel, the hospital pharmacy segment is projected to dominate with a significant share of 52.6% in 2026. The expansion is fuelled by specialist-led prescribing practices, administration demands related to biologic treatments, patient monitoring needs, reimbursement management, and integrated multidisciplinary care delivery.

According to a 2025 Scottish National Prescribing Study on advanced DMARD use, it was found that specialist hospital associated homecare and institutional pharmacy networks supplied around 78% of biologic DMARD prescriptions, demonstrating the importance of hospital-based distribution systems.

Market Drivers

Rising Adoption of Early and Intensive Treatment Strategies is Driving Growth in the Disease-Modifying Antirheumatic Drug (DMARD) Market

The Disease-Modifying Antirheumatic Drug (DMARD) Market is being driven by greater attention to early diagnosis and treat-to-target methods. Rheumatology guidelines increasingly suggest early beginning and optimization of DMARD therapy to achieve remission or low disease activity before permanent joint injury. This change has contributed to an increased use of traditional, biologic and targeted synthetic DMARDs throughout healthcare systems around the world.

According to the Arthritis Foundation reports that remission rates can be higher than 60% when rheumatoid arthritis is treated early with DMARDs and biologic treatments, but delayed treatment start is linked to significantly lower remission rates varying from 10% to 33%. These results highlight the clinical and economic implications of early diagnosis and aggressive intervention approaches.

In March 2026, EULAR issued its 2025 version of recommendations regarding the use of synthetic and biological DMARDs for treating rheumatoid arthritis and confirmed the need for prescribing DMARD treatment at the time of RA diagnosis and subsequent modifications of the treatment on a 'treat to target' principle until achieving sustained remission or low disease activity state.

Increasing Innovation in Biologics and Targeted Therapies is Transforming the DMARD Market

Continuous innovation with biologic DMARDs, biosimilar drugs, and target-specific synthetic drugs are bringing significant changes to the area of DMARD treatments. The emergence of new drugs based on innovative methods of treatment, greater efficacy, and broader indications is increasing treatment options for patients who fail to achieve adequate levels of disease control by traditional means.

In September 2024, UCB announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS).

Current Events and Their Impact

Disease-Modifying Antirheumatic Drug (DMARD) Market Trends

• Increasing adoption of biosimilar DMARDs is increasing therapy access and affordability. The Association for Accessible Medicines (AAM) 2025 Biosimilars Report found that biosimilars saved the U.S. healthcare system around USD 36 billion in 2024 alone, while increasing access to biologic treatments for millions of patients with chronic diseases, including autoimmune disorders.
• Autoimmune Disease Management Emerges for Precision Medicine and Biomarker-Based Treatment Selection. Advances in immunology and genomic profiling are allowing clinicians to adapt treatment to disease features and patient response. In a 2025 review in Frontiers in Medicine, it was noted that biomarker-guided techniques are increasingly being studied to predict treatment response and optimize DMARD selection in RA, which may improve remission rates and reduce the need for wasteful medication switching.
• Increasing Healthcare Expenditure on Rheumatic Diseases Driving Long-Term Demand for DMARDs Now governments and health care systems are focusing on measures to prevent disability and minimize the economic burden of inflammatory arthritis.

Regional Insights

North America Dominates Owing to High Adoption of Advanced DMARD Therapies and Strong Rheumatology Care Infrastructure

North America will have a 41.3% share of the Disease-Modifying Antirheumatic Drug (DMARD) Market in 2026. The expansion of the market in the region is attributed to favorable reimbursement policies, increasing usage of biologic and targeted medicines, upgraded healthcare infrastructure and increased access to rheumatology specialists. High knowledge of early diagnosis and treat-to-target techniques further helps the uptake of DMARD therapy in the region.

According to the 2025 American College of Rheumatology (ACR) Rheumatology Workforce Study, the United States had 5,667 clinically active adult rheumatologists and 379 advanced practice providers, highlighting a growing specialist workforce that supports improved access to disease-modifying therapies and comprehensive rheumatology care nationwide.

In May 2025, Teva Pharmaceuticals and Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn) as an interchangeable biosimilar to Stelara® (ustekinumab) in all presentations that match the reference product.

Asia Pacific Disease-Modifying Antirheumatic Drug (DMARD) Market Trends

The Asia Pacific region is projected to experience the fastest growth in the Disease-Modifying Antirheumatic Drug (DMARD) Market during the forecast period. Growth in the region is attributed to increased access to healthcare, increasing health insurance coverage, rising knowledge of autoimmune disorders, increasing rates of diagnosis, and increasing availability of affordable biosimilars in emerging economies such as China and India.

Furthermore, the 2025 Asia Pacific League of Associations for Rheumatology (APLAR) projects also focused on enhancing early arthritis diagnosis and expanding rheumatology capacity throughout developing Asian countries, hence promoting better access to disease-modifying medication.

In May 2024, Eisai Co., Ltd. and Nippon Medac launched Metoject Subcutaneous Injection Pen in Japan, enabling self-administration of methotrexate for rheumatoid arthritis patients.

United States Disease-Modifying Antirheumatic Drug (DMARD) Market Trends

The U.S. DMARD market is registering robust growth on the back of high disease burden, improved healthcare infrastructure, quick uptake of biologics and increasing biosimilar penetration. The country’s focus on early diagnosis and treat-to-target approaches continue to underpin long-term DMARD use in rheumatoid arthritis and other autoimmune diseases.

Moreover, the U.S. FDA’s approval of the SetPoint Medical System in July 2025 represented the first neuroimmune modulation therapy for rheumatoid arthritis patients with an inadequate response to DMARDs, a move toward innovative non-pharmacologic treatment options in the U.S. autoimmune market.

China Disease-Modifying Antirheumatic Drug (DMARD) Market Trends

China’s DMARD market is expanding rapidly, fueled by the increasing incidence of rheumatoid arthritis, better access to healthcare, robust local pharmaceutical manufacturing, and government programs that encourage biosimilars and innovation drugs.

According to a 2025 Global Burden of Disease published in Biomarker Research, East Asia (including China) accounted for a large share of the worldwide burden of rheumatoid arthritis in 2025, with the number of patients still rising due to aging populations and improved detection rates. This rising illness burden is a major driver for growing demand for DMARDs across the country.

In September 2024, China’s NMPA officially approved Xeligekimab Injection (Jinlixi), developed by Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., for the treatment of adult patients with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy.

Who are the Major Companies in Disease-Modifying Antirheumatic Drug (DMARD) Industry

Some of the major key players in Disease-Modifying Antirheumatic Drug (DMARD) Market are Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.

Key News

• In August 2025, Sanofi announced that the U.S. FDA approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP), marking a major expansion of its BTK inhibitor-based immunology portfolio.
• In September 2025, Roche announced continued expansion of its immunology pipeline focusing on IL-6 and B-cell targeted therapies for rheumatoid arthritis and lupus, reinforcing its biologic DMARD leadership strategy.

Market Report Scope

Disease-Modifying Antirheumatic Drug (DMARD) Market Report Coverage

Analyst Opinion

• The DMARD market is driven by a high and chronic illness burden. Rheumatoid arthritis affects approximately 1% of the global population (~17 million people worldwide), thereby ensuring a constant demand for long-term disease-modification therapy across all major healthcare systems.
• Targeted synthetic DMARDs and biologics are quickly changing treatment paradigms; in 2025, biologics will account for more than 45% of all rheumatoid arthritis therapy, highlighting the growing trend toward sophisticated immunology-based treatments for individuals with moderate-to-severe conditions.
• Biosimilars are greatly increasing accessibility and cost; in 2024 alone, the global use of biosimilars will result in healthcare savings of over USD 20 billion, speeding up treatment penetration in both established and emerging economies.
• More than 70% of newly diagnosed rheumatoid arthritis patients were started on methotrexate-based conventional DMARD therapy in 2024–2025 real-world studies, supporting the predominance of synthetic DMARDs as first-line treatment. Treatment guidelines and clinical practice continue to favor early intervention.

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2021-2033)
  • Synthetic (sDMARD)
    • Conventional synthetic (csDMARDs)
      • Methotrexate
      • Sulfasalazine
      • Leflunomide
      • Hydroxychloroquine
      • Gold Salts
  • Targeted synthetic DMARDs (tsDMARDs)
  • Biological DMARDs (bDMARD)
    • Original DMARDs (boDMARDs)
    • Biosimilar DMARDs (bsDMARDs)
    • Primary
    • Secondary
    • Tertiary
  • Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
  • Oral
  • Parenteral
  • Others
• By Indication (Revenue, USD Bn, 2021-2033)
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Systemic Lupus Erythematosus
  • Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Pfizer
  • Hoffman-La Roche AG
  • Johnson & Johnson
  • AbbVie Inc.
  • Eli Lilly & Company
  • Amgen Inc.
  • Swedish Orphan Biovitrum AB
  • Bristol-Myers Squibb Company
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Cumberland Pharmaceuticals Inc.

Sources

Primary Research Interviews

• Rheumatologists & Clinical Specialists
• Immunology & Autoimmune Disease Researchers
• Pharmaceutical & Biotech Companies (DMARD Developers)
• Hospital Pharmacy & Specialty Pharmacy Heads
• Clinical Trial Investigators (Rheumatology Studies)
• Healthcare Procurement & Reimbursement Experts
• Biosimilar Manufacturers & Distributors
• Others

Databases

• IQVIA (Pharmaceutical Market Data)
• GlobalData Healthcare
• Clarivate Analytics (Cortellis)
• Evaluate Pharma
• National Institutes of Health (NIH) Database
• CDC Data & Statistics
• World Health Organization (WHO) Global Health Observatory
• Others

Magazines

• Nature Reviews Rheumatology
• The Lancet Rheumatology
• Medscape Rheumatology
• Fierce Pharma
• PharmaTimes
• Endpoints News
• STAT News
• Others

Journals

• Arthritis & Rheumatology (ACR Journal)
• Annals of the Rheumatic Diseases
• Rheumatology (Oxford Academic)
• Clinical Rheumatology Journa
• Journal of Rheumatology
• Frontiers in Immunology
• Autoimmunity Reviews
• Others

Newspapers / News Portals

• Reuters Health
• Bloomberg News (Healthcare)
• Financial Times – Pharma & Biotech
• The Wall Street Journal – Healthcare
• The Economic Times – Pharma Sector
• Business Standard – Pharma & Healthcare
• PharmaVoice
• Others

Associations

• American College of Rheumatology (ACR)
• European Alliance of Associations for Rheumatology (EULAR)
• World Health Organization (WHO)
• Arthritis Foundation
• International League of Associations for Rheumatology (ILAR)
• Global Alliance for Rheumatology Registries (GARR)
• Others

Public Domain Sources

• U.S. Centers for Disease Control and Prevention (CDC)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• National Health Service (NHS) UK
• World Bank Open Data
• OECD Health Statistics
• ClinicalTrials.gov
• PubMed / NIH Research Repository
• Others

Proprietary Elements

• CMI Data Analytics Tool, Proprietary CMI Healthcare Market Intelligence Repository (10+ years historical database)